Too soon for Novartis's serelaxin, says CHMP
This article was originally published in Scrip
The EU's CHMP has knocked back Novartis's application for conditional approval of its acute heart failure treatment serelaxin (RLX030), ahead of its US FDA panel meeting in a few weeks.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.